EMA Withdrawn: Vantobra (tobramycin) — Pari Pharma GmbH

View source ↗

Summary

EMA has withdrawn Vantobra (tobramycin) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Respiratory Tract Infections

Drugs mentioned

• Vantobra

Snippet

Status: Withdrawn. Therapeutic area: Cystic Fibrosis;Respiratory Tract Infections. MAH: Pari Pharma GmbH. Decision date: 21/09/2017